Answers are grounded in this paper and cite their sources.
Chronic graft-versus-host disease (cGVHD) is diagnosed in 30%–70% of patients after allogeneic hematopoietic cell transplantation (HCT), and is a leading cause of late morbidity and non-relapse mortality [ 1 ]. Safe and effective long-term therapies are necessary to control symptomatic manifestations, and repress the disease activity causing organ damage and disability.
No takes yet. Share an insight, caveat, or question.
Kato et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: